다우존스 지수

실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.

등록

CLSD Clearside Biomedical Inc

0.9799

-0.0149 (-1.50%)

01 1월(1) 2025 - 마감

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

01/19/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ UBS Financial Services Inc, as attorney-in-fact for Charles Deignan

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Clearside Biomedical (NASDAQ:CLSD)
과거 데이터 주식 차트
부터 12월(12) 2024 으로 1월(1) 2025

Clearside Biomedical 차트를 더 보려면 여기를 클릭.

Clearside Biomedical (NASDAQ:CLSD)
과거 데이터 주식 차트
부터 1월(1) 2024 으로 1월(1) 2025

Clearside Biomedical 차트를 더 보려면 여기를 클릭.

Clearside Biomedical Inc News

Clearside Biomedical Announces Publication of Critical Insights into Retinal Drug Development in the Peer-Reviewed Scientific Journal, Eye
0년 19월 12일, 2024 (2 주 전) • GlobeNewswire Inc.

Clearside Biomedical Extends Global Footprint with Numerous Presentations at Medical Meetings in Asia, Europe and the United States
0년 25월 11일, 2024 (1 월 전) • GlobeNewswire Inc.

Form 8-K - Current report
0년 13월 11일, 2024 (2 월 전) • Edgar (US Regulatory)

Clearside Biomedical Announces Third Quarter 2024 Financial Results and Provides Corporate Update
0년 13월 11일, 2024 (2 월 전) • GlobeNewswire Inc.

Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema
0년 7월 11일, 2024 (2 월 전) • GlobeNewswire Inc.

Clearside Biomedical to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference
0년 6월 11일, 2024 (2 월 전) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
0년 5월 11일, 2024 (2 월 전) • Edgar (US Regulatory)

Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors
0년 4월 11일, 2024 (2 월 전) • GlobeNewswire Inc.

Clearside Biomedical to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Tuesday, November 12, 2024
0년 31월 10일, 2024 (2 월 전) • GlobeNewswire Inc.

Clearside Biomedical’s Positive ODYSSEY Wet AMD Data and Suprachoroidal Injection Platform Highlighted in Presentations at Multiple Events During AAO 2024 Annual Meeting
0년 22월 10일, 2024 (2 월 전) • GlobeNewswire Inc.

Form 8-K - Current report
0년 9월 10일, 2024 (3 월 전) • Edgar (US Regulatory)

Clearside Biomedical Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes
0년 9월 10일, 2024 (3 월 전) • GlobeNewswire Inc.

More Clearside Biomedical Inc News Articles

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관